Search company, investor...

Predict your next investment

GSK company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
gsk.com

Investments

53

Portfolio Exits

36

Funds

1

Partners & Customers

10

Service Providers

2

About GSK

GSK (GlaxoSmithKline) (NYSE: GSK) develops and markets pharmaceuticals, vaccines, over-the-counter medicines, and health care products. The company was founded in 1830 and is based in Middlesex, U.K.

Headquarters Location

980 Great West Road Brentford

Middlesex, England, TW8 9GS,

United Kingdom

+44 (0)20 8047 5000

Want to inform investors similar to GSK about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest GSK News

GSK’s Ojjaara approved by FDA for patients with blood cancer and anemia

Sep 18, 2023

The small molecule drug Ojjaara (momelotinib), developed by GlaxoSmithKline, has become the first U.S. Food and Drug Administration (FDA)-approved treatment for patients with the blood cancer myelofibrosis and anemia. Myelofibrosis is an uncommon form of blood cancer that can cause an enlarged spleen; constitutional symptoms such as night sweats, fever and weight loss; and scarring in the bone marrow. The bone marrow scarring also leads to severe anemia, which can cause fatigue and weakness. Blood transplants and bone marrow transplants are among the few options available for treating this condition. Compounds such as ruxolitinib and danazol can be used to treat myelofibrosis but are unable to tackle anemia. GSK’s Ojjaara is a blocker of the proteins Janus kinase (JAK) 1 and 2 as well as activin A receptor, type I (ACVR1). Given once a day, the drug is designed to combat anaemia, constitutional symptoms and splenomegaly simultaneously. The FDA initially delayed its approval decision of Ojjaara by three months in June 2023 as the regulator wanted more time to process recently submitted data from GSK. The eventual approval was based on data from the phase 3 MOMENTUM study, where Ojjaara significantly improved constitutional symptoms, splenic response and transfusion independence in patients with myelofibrosis and anemia compared with danazol. GSK also submitted data from another phase 3 trial called SIMPLIFY-1 where Ojjaara showed benefits compared with ruxolitinib in a subgroup of myelofibrosis patients with anemia. The most common adverse effects in the two trials included thrombocytopaenia, haemorrhage, bacterial infection, fatigue, dizziness, diarrhoea, and nausea. “The vast majority of myelofibrosis patients eventually develop anaemia, causing them to discontinue treatments and require transfusions,” said Nina Mojas, GSK’s senior vice president, oncology global product strategy, in a public statement. “Given this high unmet need, we are proud to add Ojjaara to our oncology portfolio and address a significant medical need in the community. We look forward to helping improve outcomes in this difficult-to-treat blood cancer.” Copyright - Unless otherwise stated all contents of this web site are © 2023 - William Reed Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions

GSK Investments

53 Investments

GSK has made 53 investments. Their latest investment was in Oncopole as part of their Corporate Minority on June 6, 2023.

CBI Logo

GSK Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/6/2023

Corporate Minority

Oncopole

$4.09M

Yes

1

9/22/2022

Corporate Minority - P2P - II

Spero Therapeutics

$9M

Yes

9

9/7/2022

Corporate Minority - P2P

SpringWorks Therapeutics

$75M

No

5

3/23/2022

Series C

Subscribe to see more

$99M

Subscribe to see more

10

1/18/2022

Corporate Minority - P2P

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/6/2023

9/22/2022

9/7/2022

3/23/2022

1/18/2022

Round

Corporate Minority

Corporate Minority - P2P - II

Corporate Minority - P2P

Series C

Corporate Minority - P2P

Company

Oncopole

Spero Therapeutics

SpringWorks Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$4.09M

$9M

$75M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

9

5

10

10

GSK Portfolio Exits

36 Portfolio Exits

GSK has 36 portfolio exits. Their latest portfolio exit was Haleon on July 18, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/18/2022

IPO

$99M

Public

1

7/17/2022

Spinoff / Spinout

$99M

2

6/17/2021

Reverse Merger

$99M

13

6/15/2021

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

2/11/2021

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/18/2022

7/17/2022

6/17/2021

6/15/2021

2/11/2021

Exit

IPO

Spinoff / Spinout

Reverse Merger

Divestiture

Divestiture

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

1

2

13

10

10

GSK Acquisitions

22 Acquisitions

GSK acquired 22 companies. Their latest acquisition was Bellus Health on June 28, 2023.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/28/2023

$99M

Acq - P2P

6

7/1/2022

Series D

$99M

$79.83M

Acq - P2P

8

5/31/2022

Grant

$99M

$369.49M

Acquired

6

9/11/2019

Series A

Subscribe to see more

$99M

$99M

Subscribe to see more

10

12/19/2018

Other

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/28/2023

7/1/2022

5/31/2022

9/11/2019

12/19/2018

Investment Stage

Series D

Grant

Series A

Other

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$79.83M

$369.49M

$99M

Note

Acq - P2P

Acq - P2P

Acquired

Subscribe to see more

Subscribe to see more

Sources

6

8

6

10

10

GSK Fund History

1 Fund History

GSK has 1 fund, including Action Potential Venture Capital Ltd..

Closing Date

Fund

Fund Type

Status

Amount

Sources

8/8/2013

Action Potential Venture Capital Ltd.

Multi-Stage Venture Capital

Closed

$50M

1

Closing Date

8/8/2013

Fund

Action Potential Venture Capital Ltd.

Fund Type

Multi-Stage Venture Capital

Status

Closed

Amount

$50M

Sources

1

GSK Partners & Customers

10 Partners and customers

GSK has 10 strategic partners and customers. GSK recently partnered with Zuellig Pharma on August 8, 2023.

Date

Type

Business Partner

Country

News Snippet

Sources

8/1/2023

Vendor

Singapore

Zuellig Pharma Singapore and GSK Establish Vaccine Distribution Hub to Improve Asia’s Access to Vaccines

Robert Kruit , EVP Strategic Partnerships & Business Development , Zuellig Pharma said : `` With the launch of GSK 's regional vaccine distribution hub , the strategic partnership between GSK and Zuellig Pharma delivers a profound , direct impact on vaccine availability in the region , while reducing the carbon footprint and setting a standard in supply chain traceability . ''

2

7/20/2023

Licensee

Switzerland

GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine

LimmaTech Biologics AG signed a research collaboration agreement with GSK to develop novel bioconjugate antigen-based vaccines including a monovalent Shigella vaccine in cooperation with the Wellcome Trust .

2

7/20/2023

Licensee

Italy

Recordati, agreement with GSK for Avodart Combodart distribution in Europe

- Recordati announced Thursday an agreement with GSK to market Avodart Combodart/Duodart in 21 countries , mainly in Europe , excluding those where GSK already has distribution agreements in place .

1

7/10/2023

Licensor

United States

Subscribe to see more

Subscribe to see more

10

6/27/2023

Vendor

United Kingdom

Subscribe to see more

Subscribe to see more

10

Date

8/1/2023

7/20/2023

7/20/2023

7/10/2023

6/27/2023

Type

Vendor

Licensee

Licensee

Licensor

Vendor

Business Partner

Country

Singapore

Switzerland

Italy

United States

United Kingdom

News Snippet

Zuellig Pharma Singapore and GSK Establish Vaccine Distribution Hub to Improve Asia’s Access to Vaccines

Robert Kruit , EVP Strategic Partnerships & Business Development , Zuellig Pharma said : `` With the launch of GSK 's regional vaccine distribution hub , the strategic partnership between GSK and Zuellig Pharma delivers a profound , direct impact on vaccine availability in the region , while reducing the carbon footprint and setting a standard in supply chain traceability . ''

GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine

LimmaTech Biologics AG signed a research collaboration agreement with GSK to develop novel bioconjugate antigen-based vaccines including a monovalent Shigella vaccine in cooperation with the Wellcome Trust .

Recordati, agreement with GSK for Avodart Combodart distribution in Europe

- Recordati announced Thursday an agreement with GSK to market Avodart Combodart/Duodart in 21 countries , mainly in Europe , excluding those where GSK already has distribution agreements in place .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

2

1

10

10

GSK Service Providers

2 Service Providers

GSK has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Acq - P2P

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Partnership data by VentureSource

GSK Team

109 Team Members

GSK has 109 team members, including current President, Russell G. Greig.

Name

Work History

Title

Status

Russell G. Greig

President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Russell G. Greig

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

President

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare GSK to Competitors

M
Mundipharma International

The Mundipharma network of independent associated companies consists of privately owned companies and joint ventures covering the world's pharmaceutical markets. These companies are committed to bringing to patients the benefits of pioneering treatment options in the core therapy areas of oncology, pain, respiratory and inflammatory conditions. They are also committed to independent thinking and ground breaking solutions. Through innovation, design and acquisition, the Mundipharma network of independent associated companies delivers cutting‐edge treatments to meet the most pressing needs of healthcare professionals and patients.

MSD Logo
MSD

Merck Sharp & Dohme (MSD), a subsidiary of Merck & Co., is a global, biopharmaceutical company bringing forward medicines and vaccines for challenging diseases.

G
Grunenthal Group

The Grunenthal Group is a science-based pharmaceutical company that seeks to bring treatments and technologies to patients worldwide. The company focuses on pain management and related diseases.

P
POSVAX

POSVAX is a biotech company that develops vaccines targeting human papillomavirus (HPV), respiratory syncytial virus (RSV), and Alzheimer's.

E
Eli Lilly and Company

Eli Lilly and Company is a drug firm that focuses on neuroscience, endocrinology, cancer, and immunology. Its key products include Verzenio for cancer, Jardiance, Trulicity, Humalog, and Humulin for diabetes, and Taltz and Olumiant for immunology. The company was founded in 1876 and is based in Indianapolis, Indiana.

Roche Logo
Roche

Roche (OTCQX: RHHBY) (OTCQX: RHHBF) operates as a multinational research-focused healthcare company. It discovers, develops, and provides diagnostic and therapeutic products and services. Roche operates worldwide under two divisions which are the pharmaceuticals division and the diagnostics division. The company was founded in 1896 and is based in Basel, Switzerland.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.